SYNCHRONY

The Phase 3 SYNCHRONY clinical trial program consists of three randomized, placebo-controlled trials:

  • SYNCHRONY Histology is evaluating the efficacy and safety of EFX in patients with biopsy-defined noncirrhotic MASH and moderate to advanced fibrosis (F2/F3);
  • SYNCHRONY Real-World is evaluating the efficacy and safety of EFX in people with noninvasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD) and mild to advanced fibrosis (F1-F4);
  • SYNCHRONY Outcomes is evaluating the efficacy and safety of EFX in people with MASH cirrhosis.
Study details are available at ClinicalTrials.gov: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. Learn more about enrolling in the SYNCHRONY Histology clinical trial.

Pipeline

We are advancing Efruxifermin (EFX) for the treatment of NASH.

View Our Pipeline